294 results on '"Berman, Robert M."'
Search Results
52. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
53. Beneficial Effects of Adjunctive Aripiprazole in Major Depressive Disorder Are Not Dependent on Antidepressant Therapy History
54. Improving Alzheimer's disease phase II clinical trials
55. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
56. Effects of Adjunctive Aripiprazole on Sexual Functioning in Patients With Major Depressive Disorder and an Inadequate Response to Standard Antidepressant Monotherapy
57. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis
58. P1-384: Predicting time to dementia based on selected MRI volumetrics and CSF measures
59. P3‐197: Exploring CSF biomarker cutpoints with penalized spline analysis and maximized log rank test
60. P3-298: The safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BMS-708163 in young and elderly subjects
61. P3-303: A placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-708163 in healthy young and elderly subjects
62. P1-387: Mild to moderate Alzheimer's disease (AD) clinical trials: The role of hippocampal atrophy as an inclusion criterion
63. O3-07-07: A study to evaluate the effects of single oral doses of BMS-708163 in the cerebrospinal fluid of healthy young men
64. P3-289: Effect of concomitant administration of multiple doses of BMS-708163 on safety, tolerability, and the pharmacokinetics of midazolam, warfarin, caffeine, omeprazole, and dextromethorphan in healthy male subjects by administration of a modified Coop
65. A Pooled MADRS/IDS Cross-Correlation Analysis
66. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies
67. Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder
68. Metabolic Assessment of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
69. P3-072: Assessing outcome measures for prodromal AD clinical trials: A retrospective analysis from the ADNI database
70. Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
71. Adjunctive Aripiprazole in Major Depressive Disorder
72. Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder
73. A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine
74. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
75. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
76. Subjective Evaluation of the Therapeutic and Cognitive Effects of ECT
77. Lifelong Course of Positive and Negative Symptoms in Chronically Institutionalized Patients with Schizophrenia
78. Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression
79. Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response
80. Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors
81. VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION
82. Monoamine depletion in unmedicated depressed subjects
83. EEG Monitoring in Depressed Patients Undergoing Repetitive Transcranial Magnetic Stimulation
84. Visual Impairment and Patterns of Winter Seasonal Depression: Seeing the Light?
85. No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects
86. Antidepressant effects of ketamine in depressed patients
87. Electroencephalogram and repetitive transcranial magnetic stimulation
88. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
89. Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated “voices”
90. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS
91. Treatment-refractory depression: Definitions and characteristics
92. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests.
93. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
94. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.
95. 5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model
96. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression.
97. Attenuation of the Neuropsychiatric Effects of Ketamine With LamotrigineN-methyl-D-aspartate Receptor Antagonists.
98. A placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-708163 in healthy young and elderly subjects
99. The safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BMS-708163 in young and elderly subjects
100. Effect of concomitant administration of multiple doses of BMS-708163 on safety, tolerability, and the pharmacokinetics of midazolam, warfarin, caffeine, omeprazole, and dextromethorphan in healthy male subjects by administration of a modified Cooperstown cocktail
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.